The Success Triangle: What MedTech Startups Can’t Ignore

When your business plan is to bring a product to the market to help people live long, healthy lives, it shouldn’t be as hard as it is to succeed — but it is. 

Founders underestimate the number of things that have to go right for a company to succeed. Their technology can work perfectly, and the clinical data can look great, yet the business is still at high risk of failure.

To succeed, founders should be encouraged to focus on the three most important things to make a medtech startup successful, or as I call it, the “success triangle”: regulatory authorization, funding, and reimbursement. Most startups over-index on one or two of these elements and assume the rest will fall into place. That’s where promising innovations stall. To reach patients, healthcare professionals, purchasers, and payers and become a profitable business, all three sides of the triangle must be built together from day one and informed by the perspectives of each of these groups.

Regulatory success is just the beginning 

Founders sometimes treat FDA authorization like the finish line when it’s really the starting gun. I’ve seen startup teams cry tears of joy the moment their device is cleared, only to realize later that getting market authorization was one of the easiest milestones to reach. Getting paid, covered, and achieving product adoption are far more challenging. 

Still, regulatory success remains the foundation, and it almost always takes longer and costs more than founders expect. A common mistake is treating quality as a compliance requirement rather than a competitive advantage. While a strong quality management system is table stakes, the overall quality of your submission, including the robustness of the supporting science, determines your speed to authorization and your credibility with investors and partners.

Companies that treat the FDA as an adversary or don’t engage with the FDA early on usually regret it. The agency’s pre-submission process exists to help you avoid deficiencies that can delay market authorization by months or even years. Skipping those early conversations can be an extremely costly or even fatal mistake.

Regulatory authorization also needs to be viewed in the context of evidence. Most startups design their first study purely around regulatory endpoints, but a study that satisfies FDA safety and efficacy endpoints will almost certainly not satisfy the evidence needs of payers or hospital value committees. Building regulatory and reimbursement evidence in parallel can shorten your time to revenue by years. 

Many startups seek the easiest regulatory path to market by pursuing lower-risk claims that entail less science and qualify for 510(k) review with no clinical evidence, rather than the intended use for which they actually want providers/patients to use their device. This strategy often leads to eventual failure. Startups that shortchange their clinical studies to save time and money risk not only FDA authorization but meaningful evidence to support adoption and reimbursement.

Fundraising for adoption, not “approval”

Every medtech founder knows they’ll need capital, but not every founder understands how much or how long it takes to reach sustainable adoption. Too many companies raise just enough to “get to FDA approval.” That may work on paper, but in practice, it leaves you stuck in the mud right after this critical milestone. Investors today often want to see early commercial traction, payer coverage, and physician adoption before committing more capital.

The solution is to fundraise to adoption milestones, not to regulatory finish lines. That means budgeting for evidence generation, payer engagement, contracting, and sales infrastructure. Sophisticated investors today underwrite to adoption, not authorization.

Founders must also understand their investors’ expectations. Some funds must return money in three years; others can hold for longer. If your path to market requires seven years and your investor’s timeline is half that, they may force a premature sale or shift your priorities in ways that reduce your upside long-term.

I’ve seen founders spend years building a product only to walk away from an acquisition with little or nothing after investors recoup their stakes. That outcome can be avoided. The right investors are the ones whose timelines match your company’s roadmap.

Reimbursement: The most misunderstood side of the triangle

Among the three sides of the triangle, reimbursement is still the most misunderstood. Founders frequently assume that if a reimbursement code exists, they’re covered. However, coding, coverage, and payment are not interchangeable. A code simply allows a provider to bill; it doesn’t guarantee that payers will cover the procedure or that the manufacturer will receive a meaningful share of the payment.

Founders often mistake the payment associated with a single CPT code as their full opportunity. They fail to realize that the device portion of the payment may only be a fraction of that amount or, worse, that payers may not cover their device at all. Others assume their newer, lower-cost alternative will inherit historical payment levels. When overall costs drop, payers are likely to recalibrate downward.

The companies that succeed treat reimbursement as design criteria. They build early relationships with payers, model economics across care settings, and incorporate health-economic and real-world endpoints into their studies. Innovators need to recognize that disruptive technologies that adversely impact existing provider reimbursement may encounter additional obstacles if that issue is not effectively addressed in their commercialization strategy. A little foresight here can save years of delay later. 

But payment is only part of the equation. Market access is just as critical. Many health systems buy products through group purchasing organizations (GPOs). If you’re not “on contract,” physicians often can’t use your product, no matter how much they want to. Some GPOs offer off-cycle pathways for breakthrough technologies or “unhealthy” categories where they want more supplier diversity, but those opportunities require evidence and planning.

Finally, don’t underestimate the influence of medical societies and key publications. Your publication strategy should start at the same time as your regulatory strategy, with the goal of publishing studies sufficient to meet the needs of payers, not just the FDA. Specialty organizations often help shape coding, coverage, and clinical guidelines. Publishing in the journals your buyers read and building advocacy within the societies that set standards can do more for adoption than a refreshed investor deck.

The point of the triangle

Most startup failures are caused by avoidable mistakes, such as misaligned investors, underfunded evidence generation plans, weak quality systems and strategy, or postponing reimbursement planning until it’s too late. 

From the earliest stages, your plan must include meaningful dialogue with patients, healthcare professionals, purchasers, and payers. Understand that their perspectives and needs will often differ, and you will constantly need to recalibrate your expectations on whether your technology is not only addressing a real clinical need but one that is worth the expense, time, and human capital that it will take to succeed in the market. 

That’s why the success triangle matters. Innovators who holistically develop their products, studies, and payment strategy with all three sides in mind will reduce risks, spend less, and reach profitability sooner. Those who don’t will learn the same hard lesson: clinical needs may open the door, but an integrated regulatory, reimbursement, and funding strategy is what lets you walk through it.

Picture: Ekspansio, Getty Images

This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.